3rej Citations

Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation.

Nucleic Acids Res 39 8200-12 (2011)
Related entries: 3reh, 3rei, 3rek, 3rel

Cited: 14 times
EuropePMC logo PMID: 21724603

Abstract

Heavy metal compounds have toxic and medicinal potential through capacity to form strong specific bonds with macromolecules, and the interaction of platinum drugs at the major groove nitrogen atom of guanine bases primarily underlies their therapeutic activity. By crystallographic analysis of transition metal-and in particular platinum compound-DNA site selectivity in the nucleosome core, we establish that steric accessibility, which is controlled by specific structural parameters of the double helix, modulates initial guanine-metal bond formation. Moreover, DNA conformational features can be linked to both similarities and distinctions in platinum drug adduct formation between the naked and nucleosomal DNA states. Notably, structures that facilitate initial platinum-guanine bond formation can oppose cross-link generation, rationalizing the occurrence of long-lived therapeutically ineffective monofunctional adducts. These findings illuminate DNA structure-dependent reactivity and provide a novel framework for understanding metal-double helix interactions, which should facilitate the development of improved chromatin-targeting medicinal agents.

Articles - 3rej mentioned but not cited (2)

  1. Specific DNA structural attributes modulate platinum anticancer drug site selection and cross-link generation. Wu B, Davey GE, Nazarov AA, Dyson PJ, Davey CA. Nucleic Acids Res 39 8200-8212 (2011)
  2. A deformation energy model reveals sequence-dependent property of nucleosome positioning. Liu G, Zhao H, Meng H, Xing Y, Cai L. Chromosoma 130 27-40 (2021)


Reviews citing this publication (5)

  1. Post-Translational Modifications of H2A Histone Variants and Their Role in Cancer. Corujo D, Buschbeck M. Cancers (Basel) 10 E59 (2018)
  2. Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies. Palermo G, Magistrato A, Riedel T, von Erlach T, Davey CA, Dyson PJ, Rothlisberger U. ChemMedChem 11 1199-1210 (2016)
  3. Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends. Groessl M, Hartinger CG. Anal Bioanal Chem 405 1791-1808 (2013)
  4. Frontiers of metal-coordinating drug design. Palermo G, Spinello A, Saha A, Magistrato A. Expert Opin Drug Discov 16 497-511 (2021)
  5. The Role of MacroH2A Histone Variants in Cancer. Hsu CJ, Meers O, Buschbeck M, Heidel FH. Cancers (Basel) 13 3003 (2021)

Articles citing this publication (7)

  1. The mechanics behind DNA sequence-dependent properties of the nucleosome. Chua EY, Vasudevan D, Davey GE, Wu B, Davey CA. Nucleic Acids Res 40 6338-6352 (2012)
  2. Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo CH, Ang WH, Dröge P, Rothlisberger U, Dyson PJ, Davey CA. Nat Commun 5 3462 (2014)
  3. Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters. Nazarov AA, Baquié M, Nowak-Sliwinska P, Zava O, van Beijnum JR, Groessl M, Chisholm DM, Ahmadi Z, McIndoe JS, Griffioen AW, van den Bergh H, Dyson PJ. Sci Rep 3 1485 (2013)
  4. An Organometallic Compound which Exhibits a DNA Topology-Dependent One-Stranded Intercalation Mode. Ma Z, Palermo G, Adhireksan Z, Murray BS, von Erlach T, Dyson PJ, Rothlisberger U, Davey CA. Angew Chem Int Ed Engl 55 7441-7444 (2016)
  5. Stereochemical control of nucleosome targeting by platinum-intercalator antitumor agents. Chua EY, Davey GE, Chin CF, Dröge P, Ang WH, Davey CA. Nucleic Acids Res 43 5284-5296 (2015)
  6. Nucleosome DNA unwrapping does not affect prototype foamy virus integration efficiency or site selection. Mackler RM, Jones ND, Gardner AM, Lopez MA, Howard CJ, Fishel R, Yoder KE. PLoS One 14 e0212764 (2019)
  7. Simultaneous mass spectrometry analysis of cisplatin with oligonucleotide-peptide mixtures: implications for the mechanism of action. Mansouri F, Patiny L, Ortiz D, Menin L, Davey CA, Mohammadi F, Dyson PJ. J Biol Inorg Chem 27 239-248 (2022)